🔥🐔 BizChicken 🐔🔥

Companies Similar to Ocular Therapeutix, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Aytu BioPharma, Inc.

Aytu BioPharma, Inc. logo
Market Cap: Lowest
Employees: Low

Adzenys XR-ODT

Aytu Biopharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics and consumer healthcare products in the United States and internationally. They offer products for the treatment of ADHD, allergies, fluoride deficiency, cough, and insomnia.

Tags: ADHD, Allergies, Fluoride Deficiency, Healthcare, Insomnia, Pharmaceuticals, Therapeutics

Symbol: AYTU

Recent Price: $1.61

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Joshua R. Disbrow

Sector: Healthcare

Employees: 102

Address: 373 Inverness Parkway, Englewood, CO 80112

Phone: 720 437 6580

Last updated: 2024-12-31

DURECT Corporation

DURECT Corporation logo
Market Cap: Lowest
Employees: Lowest

ALZET

DURECT Corporation is a biopharmaceutical company that develops medicines based on its epigenetic regulator and pharmaceutical programs. It offers products like ALZET osmotic pumps for laboratory animal research, larsucosterol for treating liver diseases, and POSIMIR for post-surgical pain relief.

Tags: ALZET, POSIMIR, biopharmaceutical, epigenetic, larsucosterol, research

Symbol: DRRX

Recent Price: $0.85

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. James E. Brown D.V.M.

Sector: Healthcare

Employees: 48

Address: 10260 Bubb Road, Cupertino, CA 95014-4166

Phone: 408 777 1417

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Revelation Biosciences, Inc.

Revelation Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

REVTx-99b

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immune system therapeutics and diagnostics, including products for chronic nasal congestion, allergic rhinitis, chronic organ disease, and viral infections.

Tags: allergic rhinitis, biopharmaceutical, clinical trial, diagnostics, immune system therapeutics, kidney disease, nasal congestion, viral infections

Symbol: REVB

Recent Price: $0.39

Industry: Biotechnology

CEO: Mr. James M. Rolke

Sector: Healthcare

Employees: 9

Address: 4660 La Jolla Village Drive, San Diego, CA 92122

Phone: 650-800-3717

Last updated: 2024-12-31

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.

Tags: TNX-102, TNX-103, TNX-201, cardiovascular, pharmaceutical, pulmonary diseases

Symbol: TENX

Recent Price: $6.55

Industry: Biotechnology

CEO: Mr. Christopher T. Giordano

Sector: Healthcare

Employees: 5

Address: ONE Copley Parkway, Morrisville, NC 27560

Phone: 919 855 2100

Last updated: 2024-12-31

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. logo
Market Cap: Lowest
Employees: Low

TNX-1500, TNX-2900, TNX-801, TNX-1840, TNX-1850, TNX-3500

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company that focuses on developing therapies for immunology, rare diseases, infectious diseases, and central nervous system disorders. Key products include TNX-1500 for organ transplant and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-801 for smallpox prevention.

Tags: CNS, autoimmunity, biopharmaceutical, cancer, immunology, infectious disease, rare disease, therapeutics

Symbol: TNXP

Recent Price: $0.36

Industry: Biotechnology

CEO: Dr. Seth Lederman M.D.

Sector: Healthcare

Employees: 103

Address: 26 Main Street, Chatham, NJ 07928

Phone: 862 799 8599

Last updated: 2024-12-31

Glaukos Corporation

Glaukos Corporation logo
Market Cap: Highest
Employees: Medium

i Stent, i Stent inject, i Stent inject W, i Stent Infinite, i Dose TR

Glaukos Corporation is a medical technology and pharmaceutical company developing therapies for glaucoma, corneal disorders, and retinal diseases. It offers micro-bypass stents and injectable implants intended to improve intraocular treatment.

Tags: corneal disorders, glaucoma treatment, i Dose TR, i Stent, medical technology, ophthalmic, pharmaceutical, retinal diseases

Symbol: GKOS

Recent Price: $149.51

Industry: Medical - Devices

CEO: Mr. Thomas William Burns

Sector: Healthcare

Employees: 907

Address: 229 Avenida Fabricante, San Clemente, CA 92672

Phone: 949 367 9600

Last updated: 2024-12-31

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

Sympazan, Suboxone, Zuplenz, Azstarys, Libervant, Exservan

Aquestive Therapeutics, Inc. is a pharmaceutical company committed to identifying, developing, and commercializing innovative products to address unmet medical needs, both in the U.S. and globally. It specializes in oral soluble film formulations for various treatments, including neurological conditions and opioid dependence.

Tags: ADHD, ALS, biotechnology, neurology, opioid dependence, oral soluble film, pharmaceutical

Symbol: AQST

Recent Price: $3.52

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Daniel Barber

Sector: Healthcare

Employees: 135

Address: 30 Technology Drive, Warren, NJ 07059

Phone: 908 941 1900

Last updated: 2024-12-31

Clearside Biomedical, Inc.

Clearside Biomedical, Inc. logo
Market Cap: Low
Employees: Lowest

XIPERE

Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. They offer treatments such as XIPERE for uveitis macular edema and are developing additional therapies for ocular conditions.

Tags: XIPERE, biopharmaceutical, clinical trials, macular edema, ocular therapies, suprachoroidal injection, uveitis

Symbol: CLSD

Recent Price: $0.99

Industry: Biotechnology

CEO: Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.

Sector: Healthcare

Employees: 30

Address: 900 North Point Parkway, Alpharetta, GA 30005

Phone: 678 270 3631

Last updated: 2024-12-31

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. logo
Market Cap: Lowest
Employees: Low

Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol, Vibativ, Redi Trex

Cumberland Pharmaceuticals Inc. focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology, offering various medications including injections and oral solutions.

Tags: gastroenterology, hospital care, oncology, pharmaceutical, prescription products, rheumatology

Symbol: CPIX

Recent Price: $2.42

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. A. J. Kazimi MBA

Sector: Healthcare

Employees: 91

Address: 2525 West End Avenue, Nashville, TN 37203

Phone: 615 255 0068

Last updated: 2024-12-31

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

Biorphen, Carglumic Acid, Rezipres, Alkindi Sprinkle, EPRONTIA, Alaway Preservative Free

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for rare diseases, with a portfolio including treatments like Biorphen, Carglumic Acid, and others for various indications.

Tags: Alaway Preservative Free, Alkindi Sprinkle, Biorphen, Carglumic Acid, EPRONTIA, Pharmaceuticals, Rare Diseases, Rezipres

Symbol: ETON

Recent Price: $13.03

Industry: Biotechnology

CEO: Mr. Sean E. Brynjelsen

Sector: Healthcare

Employees: 30

Address: 21925 West Field Parkway, Deer Park, IL 60010-7208

Phone: 847 787 7361

Last updated: 2024-12-31

EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

ILUVIEN, YUTIQ, DEXYCU, EYP-1901, YUTIQ50

Eye Point Pharmaceuticals, Inc. develops and commercializes ophthalmic products for treating eye diseases, including innovative treatments like ILUVIEN, YUTIQ, and DEXYCU. Their efforts serve the United States, China, and the United Kingdom, focusing on diseases such as diabetic macular edema and chronic non-infectious uveitis.

Tags: DEXYCU, ILUVIEN, YUTIQ, biotechnology, eye diseases, eye health, micro-insert, ophthalmic, ophthalmology, pharmaceutical, treatment, vision

Symbol: EYPT

Recent Price: $7.02

Industry: Biotechnology

CEO: Dr. Jay S. Duker M.D.

Sector: Healthcare

Employees: 121

Address: 480 Pleasant Street, Watertown, MA 02472

Phone: 617 926 5000

Last updated: 2024-12-31

IRIDEX Corporation

IRIDEX Corporation logo
Market Cap: Lowest
Employees: Low

Cyclo G6 laser system, IQ 532, and IQ 577 laser photocoagulation systems

IRIDEX Corporation is an ophthalmic medical technology company offering laser systems and devices for the treatment of sight-threatening eye diseases like glaucoma, diabetic macular edema, and retinal diseases.

Tags: diabetic macular edema, eye diseases, glaucoma treatment, medical lasers, ophthalmic technology, retinal diseases

Symbol: IRIX

Recent Price: $1.74

Industry: Medical - Devices

CEO: Mr. Patrick Mercer

Sector: Healthcare

Employees: 111

Address: 1212 Terra Bella Avenue, Mountain View, CA 94043

Phone: 650 940 4700

Last updated: 2024-12-31

Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KIO-301

Kiora Pharmaceuticals, Inc. develops therapies for ophthalmic diseases, with lead product KIO-301 in Phase 1 trial for vision restoration in degenerative retinal diseases and other products in trials for conditions like rheumatoid arthritis-related ocular issues and corneal wound repair.

Tags: clinical trials, ophthalmic diseases, ophthalmology, pharmaceuticals, vision restoration

Symbol: KPRX

Recent Price: $3.30

Industry: Biotechnology

CEO: Dr. Brian M. Strem Ph.D.

Sector: Healthcare

Employees: 12

Address: 1371 East 2100 South, Salt Lake City, UT 84105

Phone: 781 788 8869

Last updated: 2024-12-31

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. logo
Market Cap: High
Employees: Low

Re Sure Sealant; DEXTENZA; OTX-TKI; OTX-TIC; OTX-CSI

Ocular Therapeutix is a biopharmaceutical company that develops and commercializes therapies for eye diseases using bioresorbable hydrogel-based technology, offering products like Re Sure Sealant and DEXTENZA.

Tags: biopharmaceutical, eye care, hydrogel, ophthalmic devices, ophthalmology, therapy

Symbol: OCUL

Recent Price: $8.35

Industry: Biotechnology

CEO: Dr. Pravin U. Dugel M.D.

Sector: Healthcare

Employees: 267

Address: 24 Crosby Drive, Bedford, MA 01730

Phone: 781 357 4000

Leadership

  • Pravin U. Dugel, MD, Executive Chairman, President and CEO
  • Karen-Leigh Edwards, PhD, MBA, Chief Operations Officer
  • Peter Jarrett, PhD, Chief Technical Officer
  • Donald Notman, Chief Financial Officer and Chief Operating Officer
  • Nadia K. Waheed, MD, MPH, Chief Medical Officer
  • Jeffrey S. Heier, MD, Chief Scientific Officer
  • Steve Meyers, Chief Commercial Officer
  • Tracy Smith, Vice President, Human Resources
  • Sanjay Nayak, MBBS, PhD, Chief Strategy Officer
  • Peter K. Kaiser, MD, Chief Development Officer
  • Todd Anderman, JD, Chief Legal Officer and Corporate Secretary
  • Charles Warden, Lead Independent Director
  • Adrienne Graves, PhD, Director
  • Leslie Williams, Director
  • Richard Lindstrom, MD, Director
  • Seung Suh Hong, PhD, Director
  • Merilee Raines, Director

Last updated: 2024-12-31

Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

ONS-5010

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing monoclonal antibodies for ophthalmic indications, with its lead product candidate ONS-5010 in Phase-III clinical trial for treating wet age-related macular degeneration and other retina diseases.

Tags: biopharmaceutical, clinical trial, monoclonal antibodies, ophthalmic, retina diseases

Symbol: OTLK

Recent Price: $1.86

Industry: Biotechnology

CEO: Mr. C. Russell Trenary III

Sector: Healthcare

Employees: 24

Address: Building F, Iselin, NJ 08852

Phone: 609 619 3990

Leadership

  • Randy Thurman, Executive Chairman
  • Yezan Haddadin, Member of the Board of Directors
  • Kurt J. Hilzinger, Member of the Board of Directors
  • Julia A. Haller, MD, Member of the Board of Directors
  • C. Russell Trenary III, President, Chief Executive Officer, and Member of the Board
  • Lawrence A. Kenyon, Chief Financial Officer and Member of the Board
  • Faisal G. Sukhtian, Executive Director
  • Julian Gangolli, Member of the Board of Directors
  • Gerd Auffarth, MD, Member of the Board of Directors
  • Andong Huang, Vice President, Business Development

Last updated: 2024-12-31

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. logo
Market Cap: High
Employees: Medium

Crysvita, Mepsevii, Dojolvi, Evkeeza, DTX401, DTX301

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare and ultra-rare genetic diseases worldwide.

Tags: Crysvita, Dojolvi, Evkeeza, Mepsevii, biopharmaceutical, gene therapy, genetic diseases, rare diseases

Symbol: RARE

Recent Price: $42.27

Industry: Biotechnology

CEO: Dr. Emil D. Kakkis M.D., Ph.D.

Sector: Healthcare

Employees: 1276

Address: 60 Leveroni Court, Novato, CA 94949

Phone: 415 483 8800

Last updated: 2024-12-31

RxSight, Inc.

RxSight, Inc. logo
Market Cap: High
Employees: Medium

Rx Sight system

Rx Sight, Inc. is a medical technology company specializing in light adjustable intraocular lenses used in cataract surgery, allowing for post-operative customization of visual acuity.

Tags: Rx Sight system, cataract surgery, intraocular lenses, medical technology, visual acuity

Symbol: RXST

Recent Price: $33.81

Industry: Medical - Devices

CEO: Dr. Ronald M. Kurtz M.D.

Sector: Healthcare

Employees: 374

Address: 100 Columbia, Aliso Viejo, CA 92656

Phone: 949 521 7830

Last updated: 2024-12-31

Sight Sciences, Inc.

Sight Sciences, Inc. logo
Market Cap: Low
Employees: Low

OMNI Surgical System, Tear Care System

Sight Sciences, Inc., is a company focused on developing and commercializing surgical and nonsurgical technologies for treating eye diseases, including products like the OMNI Surgical System for glaucoma and Tear Care System for dry eye disease.

Tags: dry eye disease, eye diseases, glaucoma, healthcare, medical device, ophthalmic, technology

Symbol: SGHT

Recent Price: $3.53

Industry: Medical - Devices

CEO: Mr. Paul Badawi

Sector: Healthcare

Employees: 214

Address: 4040 Campbell Avenue, Menlo Park, CA 94025

Phone: 877 266 1144

Last updated: 2024-12-31

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

VTX958

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates for the treatment of inflammatory diseases and autoimmune disorders. Key products include VTX958 for immune-mediated diseases, VTX002 for ulcerative colitis, and VTX2735 for systemic inflammatory diseases.

Tags: VTX002, VTX2735, VTX958, autoimmune disorders, biopharmaceutical, clinical trials, inflammatory diseases, small molecule

Symbol: VTYX

Recent Price: $2.23

Industry: Biotechnology

CEO: Dr. Raju S. Mohan Ph.D.

Sector: Healthcare

Employees: 73

Address: 662 Encinitas Boulevard, Encinitas, CA 92024

Phone: 760 593 4832

Last updated: 2024-12-31